Translational Development Acquisition Corp. (TDAC) Stock Overview
Explore Translational Development Acquisition Corp.’s financial performance, market position, analyst ratings, and future outlook.
Translational Development Acquisition Corp. (TDAC)
Key Financials
Key Financials
Market Cap
267.2M
P/E Ratio
42.18
EPS (TTM)
$0.25
ROE
0.03%
TDAC Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Translational Development Acquisition Corp. (NASDAQ: TDAC) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Translational Development Acquisition Corp.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of TDAC on the NASDAQ shows an RSI of 49.27, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $11.10 for the NASDAQ listing.
Key metrics behind Translational Development Acquisition Corp.'s NASDAQ-traded stock include a P/E ratio of 42.18 and a market capitalization of 267.2M. Combined with our AI analysis, these give both institutional and retail investors a clear view of TDAC on the NASDAQ.